Mouse models mimicking the transition from a common form of lung cancer to a more aggressive one may help scientists develop ...

In the fight to cure cancer, scientists need better models. And they might just get them — human-derived organoids — thanks ...

Although drugs targeting oncogenic driver mutations have significantly improved survival but their long-term responses are still uncommon for most patients, the emergence of acquired drug ...

The new company, BridgeBio Oncology Therapeutics, is looking to advance two KRAS inhibitors and a blocker of the interaction ...

Leading oncology drug developers raise $67 million in funding to target cancer's vulnerability to oncogene overactivation.

BOSTON--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is ...

It’s said that ancient Greeks inscribed an aphorism in the forecourt of the Temple of Apollo at Delphi: “Nothing in excess.” Enter Delphia Therapeutics, a start-up harnessing the notion of excess to ...

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced an oral ...

"Despite dramatic advances in the understanding and drugging of key driver mutations and oncogenic pathways, cancer remains a tremendous global health challenge, as tumors rapidly develop resistance ...

A hotly debated topic in online relationship spaces is the role of sexual history (“body count”, “notches on the bedpost”) in ...

The discovery of oncogenic driver alterations and target therapy have brought significant clinical benefits and established ...